• 2015
  Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F, , Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial, Lancet Infect Dis 2015 Nov;15(11):1283-91.
• 2015
  Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML, Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes, Vaccine 2015 Aug;33(36):4548-53.
• 2015
  Rivière L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, Buendia MA, Hantz O, Neuveut C, HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase, J. Hepatol. 2015 Nov;63(5):1093-102.
• 2015
  Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F, Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure, Gut 2015 Aug;64(8):1314-26.
• 2015
  Schleef M, Schirmbeck R, Reiser M, Michel ML, Schmeer M, Minicircle: Next Generation DNA Vectors for Vaccination, Methods Mol. Biol. 2015;1317:327-39.
• 2014
  Michel ML, Bourgine M, Fontaine H, Pol S, Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?, Med. Microbiol. Immunol. 2015 Feb;204(1):121-9.
• 2014
  Martin P, Dubois C, Jacquier E, Dion S, Mancini-Bourgine M, Godon O, Kratzer R, Lelu-Santolaria K, Evlachev A, Meritet JF, Schlesinger Y, Villeval D, Strub JM, Van Dorsselaer A, Marchand JB, Geist M, Brandely R, Findeli A, Boukhebza H, Menguy T, Silvestre N, Michel ML, Inchauspé G, TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice, Gut 2014 Nov;.
• 2014
  Serra-Hassoun M, Bourgine M, Boniotto M, Berges J, Langa F, Michel ML, Freitas AA, Garcia S, Human hematopoietic reconstitution and HLA-restricted responses in nonpermissive alymphoid mice, J. Immunol. 2014 Aug;193(3):1504-11.
• 2014
  Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A, Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection, PLoS ONE 2014;9(3):e92140.
• 2013
  Wang Z, Zhu K, Bai W, Jia B, Hu H, Zhou D, Zhang X, Zhang X, Xie Y, Bourgine MM, Michel ML, Lan K, Deng Q, Adenoviral delivery of recombinant hepatitis B virus expressing foreign antigenic epitopes for immunotherapy of persistent viral infection, J. Virol. 2014 Mar;88(5):3004-15.
• 2013
  Dion S, Bourgine M, Godon O, Levillayer F, Michel ML, Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules, J. Virol. 2013 May;87(10):5554-63.
• 2012
  Bourgine M, Dion S, Godon O, Guillen G, Michel ML, Aguilar JC, Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model, Virology 2012 Aug;430(1):10-9.
• 2011
  Zhu R, Mancini-Bourgine M, Zhang XM, Bayard F, Deng Q, Michel ML, Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice, J. Virol. 2011 Oct;85(19):10201-12.
• 2011
  Michel ML, Deng Q, Mancini-Bourgine M, Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges, J. Hepatol. 2011 Jun;54(6):1286-96.
• 2010
  Bayard F, Malmassari S, Deng Q, Lone YC, Michel ML, Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo, Vaccine 2010 May;28(22):3818-26.
• 2010
  Scott-Algara D, Mancini-Bourgine M, Fontaine H, Pol S, Michel ML, Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination, PLoS ONE 2010 Jan;5(1):e8761.
• 2009
  Deng Q, Mancini-Bourgine M, Zhang X, Cumont MC, Zhu R, Lone YC, Michel ML, Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models, Hepatology 2009 Nov;50(5):1380-91.
• 2007
  Mancini-Bourgine M, Bayard F, Soussan P, Deng Q, Lone YC, Kremsdorf D, Michel ML, Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients, J. Virol. 2007 May;81(10):4963-72.
• 2006
  Pajot A, Michel ML, Mancini-Bourgine M, Ungeheuer MN, Ojcius DM, Deng Q, Lemonnier FA, Lone YC, Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects, Microbes Infect. 2006 Oct;8(12-13):2783-90.
• 2005
  Michel ML, Mancini-Bourgine M, Therapeutic vaccination against chronic hepatitis B virus infection, J. Clin. Virol. 2005 Dec;34 Suppl 1:S108-14.
• 2005
  Mancini-Bourgine M, Fontaine H, Bréchot C, Pol S, Michel ML, Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers, Vaccine 2006 May;24(21):4482-9.
• 2005
  Puaux AL, Delache B, Marconi S, Huerre M, Le Grand R, Rivière Y, Michel ML, Loss of reactivity of vaccine-induced CD4 T cells in immunized monkeys after SIV/HIV challenge, AIDS 2005 May;19(8):757-65.
• 2005
  Mancini-Bourgine M, Michel ML, [Therapeutic vaccination against chronic hepatitis B virus infection], Therapie 2005 May-Jun;60(3):257-65.
• 2005
  Malmassari S, Lone YC, Zhang M, Transy C, Michel ML, In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus, Microbes Infect. 2005 Apr;7(4):626-34.
• 2005
  Marsac D, Puaux AL, Rivière Y, Michel ML, In vivo induction of cellular and humoral immune responses by hybrid DNA vectors encoding simian/human immunodeficiency virus/hepatitis B surface antigen virus particles in BALB/c and HLA-A2-transgenic mice, Immunobiology 2005;210(5):305-19.
• 2004
  Pajot A, Michel ML, Fazilleau N, Pancré V, Auriault C, Ojcius DM, Lemonnier FA, Lone YC, A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice, Eur. J. Immunol. 2004 Nov;34(11):3060-9.
• 2004
  Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel ML, Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers, Hepatology 2004 Oct;40(4):874-82.
• 2004
  Puaux AL, Marsac D, Prost S, Singh MK, Earl P, Moss B, Le Grand R, Riviere Y, Michel ML, Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles, Vaccine 2004 Sep;22(27-28):3535-45.
• 2004
  Pajot A, Pancré V, Fazilleau N, Michel ML, Angyalosi G, Ojcius DM, Auriault C, Lemonnier FA, Lone YC, Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules, Int. Immunol. 2004 Sep;16(9):1275-82.
• 2003
  Puaux AL, Michel ML, New gene-based approaches for an AIDS vaccine, Comp. Immunol. Microbiol. Infect. Dis. 2003 Oct;26(5-6):357-72.